Written by Dan Cripe, RN, BSN & Marcia Cripe, RN

Food Apathy vs. Appetite Suppression on a GLP-1: When “Not Hungry” Becomes “I Don’t Care About Food”

You expected your GLP-1 to make you less hungry. You may even have hoped food would stop occupying so much space in your mind. But there can be a point when “I’m not very hungry” begins to feel more like “I genuinely don’t care whether I eat,” and those are not necessarily the same experience.

Normal GLP-1 appetite suppression can make hunger less frequent, portions smaller, cravings quieter, and food much easier to stop thinking about. Food apathy goes a step further: deciding what to eat feels like work, meals keep getting postponed because nothing seems worth the effort, and you may struggle to eat enough even though you know your body still needs food.

That distinction matters because reducing appetite and food intake is part of what medications such as semaglutide and tirzepatide are designed to do. When that effect becomes strong enough that you routinely have difficulty nourishing or hydrating yourself, however, the question changes from “Is my medication working?” to “Is this level of appetite suppression still working well for me?”

There is another important distinction to make from the beginning. Losing interest in food is not automatically the same as losing interest or pleasure in life more broadly. If the same sense of flatness begins spreading into your hobbies, relationships, exercise, work, sex, social life, or other things you normally enjoy, that deserves a broader clinical assessment rather than being dismissed as ordinary appetite suppression.

Appetite Suppression Is Supposed to Change Your Relationship With Food

If you have spent years feeling hungry frequently, thinking about food between meals, battling cravings, or needing considerable effort to stop eating when food still looks appealing, effective GLP-1 treatment can feel surprisingly different. You may suddenly realize lunchtime is approaching and you have not thought about food all morning, or you may order the same restaurant meal you once finished easily and feel perfectly satisfied after half of it.

You might also notice foods that once seemed difficult to resist without feeling particularly pulled toward them anymore. Cookies can sit in the break room without becoming a mental negotiation, and deciding not to have dessert may feel almost effortless rather than requiring willpower. Those changes can be part of the intended treatment effect.

GLP-1-based medications can influence hunger, satiation, cravings, responsiveness to food cues, and overall energy intake. Tirzepatide has demonstrated substantial effects on several of these behaviors in controlled human research, suggesting that its influence on eating extends well beyond simply making your stomach feel physically full.

In a randomized Phase 1 study involving adults with overweight or obesity, participants receiving tirzepatide consumed approximately 525 fewer calories during an unrestricted lunch than participants receiving placebo at Week 3. They also reported reductions in hunger, appetite, cravings, overeating tendencies, and responsiveness to food cues.

That does not mean you should expect—or try—to eat exactly 525 fewer calories at lunch when taking tirzepatide. The finding is useful because it demonstrates just how strongly the medication can alter eating behavior under controlled conditions and why the change can feel dramatically different from simply trying harder to eat less.

Hunger, Food Noise, and Food Reward Are Not the Same Thing

When you say your “appetite” has disappeared, it helps to identify exactly what has changed because several different systems contribute to your relationship with food. Hunger, food noise, and food reward overlap, but they are not interchangeable, and a GLP-1 can influence each of them somewhat differently.

Hunger is part of the physiological drive that motivates you to eat. It is influenced by your energy status, gastrointestinal signals, hormones, learned eating patterns, and brain systems involved in regulating energy balance.

Food noise describes the persistent mental preoccupation with food that many people experience. You may think about what you are going to eat later, negotiate with yourself about whether you should have something, notice food constantly, or feel mentally pulled toward eating even when you are not physically hungry.

Food reward is slightly different because it relates to how motivating, desirable, or pleasurable food and food-related cues feel to you. Food can still taste perfectly acceptable while losing much of the motivational pull that once made you think about it, seek it out, or go to considerable effort to obtain it.

A GLP-1 can affect all three of these experiences, but they do not necessarily change together. You may still experience normal stomach hunger while having almost no food noise, or your cravings may disappear long before your physical hunger does.

You can also become physically hungry while feeling strangely unmotivated to decide what to eat, prepare it, order it, or go get it. That pattern is often what people are trying to describe when they say food has become uninteresting rather than simply saying their appetite is smaller.

You Can Still Like Food Without Particularly Wanting It

Reward science gives us a useful framework for understanding this experience because liking and wanting are related, but they are not identical. “Liking” broadly describes the pleasure you experience once you consume something, while “wanting” describes more of its motivational pull—the feeling that makes obtaining it seem worth the effort in the first place.

You may still enjoy pizza once someone puts a slice in front of you, for example, but have absolutely no motivation to choose a restaurant, place the order, wait for it, or drive somewhere to pick it up. The food itself can still taste good while the chain of motivation that normally gets you from “pizza sounds good” to actually obtaining pizza has become much weaker.

For some people taking a GLP-1, that distinction describes the experience better than saying food tastes bad or that appetite has simply decreased. Food may still be enjoyable once you eat it; you just do not care enough about it to pursue it.

Your Food Can Taste the Same While Feeling Much Less Important

Emerging human research supports the idea that GLP-1 treatment may change your behavioral response to food more dramatically than it changes your basic ability to taste or smell it. That distinction matters because many people assume food must taste different if they suddenly care much less about eating it.

A 2026 study examined sensory function, food noise, cravings, responses to food cues, food reward, and dietary intake among adults with obesity before GLP-1 treatment and after one or six months of GLP-1 receptor agonist use. Most measures involving taste intensity, pleasantness, smell, and related sensory function did not show dramatic differences.

The behavioral measures were more notable. Participants with longer GLP-1 exposure had lower food noise, cravings, responsiveness to food cues, food reward, and energy intake, suggesting that the medication's influence may be especially important in how strongly food captures your attention and motivates eating behavior.

This was a relatively small cross-sectional study, so it cannot establish that the medication directly caused every difference researchers observed. It does, however, help explain an experience you may recognize: food does not have to taste terrible for you to stop feeling particularly interested in it.

The food itself may taste almost exactly as it did before treatment. What has changed may be how important, compelling, or worth pursuing it feels to you.

Why Can a Gut-Hormone Medication Affect How Much You Care About Food?

GLP-1 biology is not confined to your stomach. GLP-1-related signaling interacts with brain systems involved in energy regulation, satiation, learning, motivation, decision-making, and reward, which helps explain why these medications can affect much more than stomach fullness alone.

Research has examined areas including the brainstem, hypothalamus, amygdala, orbitofrontal cortex, ventral tegmental area, and nucleus accumbens. The ventral tegmental area and nucleus accumbens are particularly interesting because they participate in circuits involved in motivation, reinforcement, and reward-seeking behavior.

That does not mean your GLP-1 simply “switches off” the reward center in your brain, and it does not mean the medication merely lowers dopamine. Human reward biology is substantially more complicated than either explanation suggests.

A 2026 systematic review examining GLP-1 signaling and the nucleus accumbens found only a small number of eligible human studies, and researchers did not identify evidence for a simple increase-or-decrease effect on nucleus accumbens activity. Instead, GLP-1 signaling may influence how different reward-related regions communicate and respond to metabolic information.

A more accurate way to think about the effect is that your GLP-1 may be changing how strongly food captures your attention and motivates you to act. Researchers are still working out exactly how those changes occur in humans, so it is better to describe the evidence carefully than to reduce the entire experience to dopamine.

Tirzepatide Changes More Than Stomach Fullness

Tirzepatide research provides another clue that these medications affect eating behavior beyond making you feel full sooner. In the randomized eating-behavior study, tirzepatide reduced measured food intake while also reducing hunger, cravings, overeating tendencies, and responsiveness to food in the environment.

Functional brain imaging performed as part of the research also identified changes in responses to certain highly palatable food images in regions involved in reward, decision-making, memory, and food-related processing. That does not prove there is one specific brain circuit responsible for food apathy, but it reinforces the idea that the medication's effects extend well beyond digestion.

That is why the common explanation “food stays in your stomach longer, so you eat less” is incomplete. Tirzepatide can influence how food is anticipated, noticed, pursued, and consumed, all of which can contribute to the experience of food suddenly feeling much less important.

When Does “I’m Less Hungry” Become a Problem?

You do not need to be excited about every meal for your GLP-1 treatment to be going well. The more useful question is whether your reduced interest in food is beginning to interfere with your ability to eat enough to support your body.

Imagine that you rarely think about food anymore, but around lunchtime you recognize some hunger, choose something to eat, enjoy a smaller portion, feel satisfied, and eat again later in the day. That pattern looks very different from repeatedly reaching the evening and realizing that you have consumed coffee, half a protein shake, and a few bites of something because deciding what to eat or obtaining food felt like too much effort.

Both experiences involve reduced appetite, but the second is much more likely to interfere with nutrition. Once meals are repeatedly disappearing from your day because you cannot make yourself care enough to eat them, the issue is no longer simply whether the medication is suppressing your appetite effectively.

The more important question becomes whether you are still able to adequately nourish yourself while taking it. Appetite suppression is helpful when it makes eating feel more manageable; it becomes less helpful when it makes meeting your basic nutritional needs increasingly difficult.

Food Apathy Makes Significant Undereating Surprisingly Easy

One of the strange things about profound appetite suppression is that you may not feel particularly distressed about how little you are eating. You are not necessarily sitting there desperately hungry while deliberately restricting food; you may genuinely feel comfortable skipping it.

That is precisely why significant undereating can sneak up on you. Hunger normally acts as one of the signals reminding you to seek food, and when that signal becomes very quiet, your actual intake can fall considerably before you recognize there is a problem.

Your body continues to require energy, protein, essential fats, carbohydrates, vitamins, minerals, and fluid even when your brain is producing very little motivation to obtain them. A quiet appetite changes how strongly you feel the need to eat; it does not eliminate the physiological need itself.

Over time, inadequate intake may contribute to fatigue, weakness, feeling cold, dizziness, difficulty concentrating, poorer exercise tolerance, and loss of lean tissue. None of those symptoms proves that inadequate nutrition is the cause because they can occur for many reasons, but your actual food and fluid intake should be part of the assessment when your appetite has become extremely low.

Protein Matters, but You Cannot Live on Protein Alone

When your appetite is limited, prioritizing protein makes sense. Significant weight loss can include loss of lean tissue as well as body fat, and adequate protein combined with resistance exercise, when medically appropriate, can help support muscle and physical function.

The problem is that protein can become the only nutritional goal you are paying attention to. Your entire day may quietly turn into a protein shake, yogurt, a few bites of chicken, and very little else, leaving you focused on protein while still consuming inadequate overall nutrition.

Your body also requires sufficient total energy, dietary fat, carbohydrates according to your individual needs and tolerance, vitamins, minerals, fiber, and fluid. Hitting a protein target does not automatically mean you are eating enough to support everything your body needs.

Food apathy therefore cannot always be solved by trying to squeeze more protein into the few bites you are still willing to eat. The larger goal is adequate overall nutrition in an amount and form you can realistically tolerate.

Hydration Can Become Part of the Same Problem

Food and fluid intake are often more connected than they seem. Meals provide fluid through the foods themselves while also creating predictable opportunities to drink, so when breakfast disappears, lunch becomes a few bites, and dinner keeps getting pushed later, some of your usual hydration opportunities disappear along with them.

Nausea, constipation, diarrhea, vomiting, reflux, and early fullness can make the situation even more complicated. If drinking also contributes to uncomfortable fullness or nausea, you may gradually consume less fluid without consciously deciding to do so.

You may therefore need to become more deliberate about hydration when your appetite becomes extremely low. That does not mean forcing enormous amounts of water into an already full stomach; it means recognizing that your fluid needs did not disappear simply because your eating pattern changed.

If you are struggling to maintain both food and fluid intake, that deserves more attention than simply describing yourself as “not hungry.” At that point, reduced appetite is beginning to interfere with basic self-care rather than simply making weight management easier.

Food Apathy Is Not Automatically Anhedonia

This is an important boundary because losing interest in food and losing the ability to experience pleasure throughout your life are not the same thing. Anhedonia refers to a diminished capacity to experience interest or pleasure in things that would normally be rewarding and is associated with depression as well as other psychiatric and neurological conditions.

Losing your fascination with cheesecake does not establish anhedonia, and neither does realizing you could happily skip lunch because food simply does not hold much interest anymore. What matters is whether that indifference remains relatively specific to food or begins appearing across the rest of your life.

Ask yourself what still feels rewarding. Do you enjoy spending time with people you love, listening to music, exercising, traveling, shopping, having sex, working on hobbies, planning things you look forward to, or participating in whatever normally makes your life feel interesting and meaningful?

If food is unusually uninteresting while the rest of your reward system seems intact, your experience may fit much better with altered appetite and food motivation. The clinical picture becomes different when the same sense of flatness begins spreading beyond eating.

What If You Do Not Care About Much of Anything Anymore?

A broader loss of motivation or pleasure deserves more attention than food apathy alone. In 2026, researchers published a small case series describing anhedonia-like symptoms in three women receiving high-dose tirzepatide, all of whom were taking 15 mg weekly.

The women described changes including diminished motivation, emotional flatness, or reduced interest in exercise and other activities they had previously enjoyed. Their symptoms reportedly appeared after prolonged treatment at or near the maximum dose, and all three eventually reduced their tirzepatide dose to 10 mg weekly or lower.

Two reported substantial improvement in motivation and enjoyment after dose reduction alone. One patient also received bupropion, while another reportedly experienced recurrence of symptoms when tirzepatide was increased again followed by improvement when the dose was reduced.

That pattern is clinically interesting, but three patients cannot tell us how often this occurs, whether tirzepatide directly caused the symptoms, whether the phenomenon occurs with other GLP-1 medications, or how it should generally be managed. It is best understood as a signal worth studying rather than proof that tirzepatide commonly causes anhedonia.

Larger Studies Give a More Reassuring Picture

Small case reports are useful for identifying unusual experiences, but population-level evidence gives us a better sense of whether those experiences appear common across large groups of patients. A much larger 2026 observational study compared neuropsychiatric outcomes among patients receiving tirzepatide, semaglutide, and other GLP-1 receptor agonists.

After matching, the tirzepatide-versus-semaglutide analysis included more than 85,000 patient pairs. Over two years, researchers found broadly comparable risks for the composite psychiatric outcome, which included depression, anxiety, and suicidal ideation.

A possible anxiety signal appeared with tirzepatide during the second year, but the researchers cautioned against overinterpreting that finding because multiple statistical comparisons were performed. Overall, the larger evidence does not suggest that tirzepatide routinely causes major psychiatric problems.

That does not mean an individual person cannot experience an unusual neurobehavioral effect. Both things can be true at the same time: uncommon individual experiences may deserve careful investigation while the larger available evidence remains broadly reassuring.

Does Your GLP-1 “Lower Dopamine”?

You may see the explanation “GLP-1 medications lower dopamine” frequently online because it provides an appealingly simple reason for why food, alcohol, shopping, or other rewards may suddenly feel less compelling. Unfortunately, human neurobiology is much more complicated than that explanation suggests.

Dopamine participates in motivation, learning, attention, movement, reinforcement, and many other functions. Reward processing also involves numerous other neurotransmitters, brain regions, hormonal signals, and networks working together rather than a single chemical that can simply be turned up or down.

GLP-1 receptors interact with parts of these reward pathways, and preclinical research supports interactions with dopaminergic signaling. Current human evidence, however, does not justify reducing the experience to GLP-1 → lower dopamine → less pleasure.

A better interpretation is that GLP-1 signaling appears capable of changing how metabolic information interacts with brain systems involved in motivation and reward. That may help explain why food becomes less compelling without requiring the conclusion that your brain has simply “run out of dopamine.”

A Better Way to Figure Out What You Are Experiencing

Instead of asking only whether you are hungry, it can be more useful to look at three separate areas: hunger, eating function, and broader reward. This gives you a clearer picture of whether your experience still looks like ordinary appetite suppression or whether it is beginning to interfere with your health or functioning.

With typical appetite suppression, you may feel less hungry, become satisfied sooner, think about food much less, and eat smaller portions while still being able to recognize that you need food and eat adequately. Food may occupy much less mental space without becoming difficult to consume.

With stronger food apathy, you may repeatedly postpone or skip meals because choosing food feels burdensome, nothing seems worth obtaining, and eating enough requires increasing conscious effort. The problem is no longer simply that you are less hungry; eating itself is beginning to require a level of effort that interferes with adequate intake.

With broader anhedonia-like symptoms, the same loss of interest begins appearing outside food. Exercise you once loved may feel pointless, hobbies may stop holding your attention, socializing may seem unimportant, or experiences that normally feel rewarding may begin to feel strangely flat.

These are not formal diagnostic categories, and they should not be used to diagnose yourself. They are simply a practical framework for deciding whether your experience seems limited to the expected effects on appetite and food motivation or whether it deserves a broader conversation with your healthcare provider.

When Appetite Is Too Quiet, Structure Can Take Over

If you wait until food sounds appealing, you may discover that very little eating happens. When appetite is no longer providing reliable reminders, external structure can temporarily take over some of that job.

Instead of asking whether you want breakfast, lunch, or dinner, you may need to create regular opportunities to eat because you know your body still requires nutrition. The goal is not to force yourself through large meals when you are uncomfortable; smaller, more manageable eating opportunities may work much better when appetite is extremely low.

Reducing the amount of decision-making involved can help too. If deciding what to eat is the biggest barrier, keep a few foods available that require very little planning, preparation, or cleanup so eating does not become a complicated project every time.

Depending on your needs and tolerance, options might include yogurt, cottage cheese, eggs, soup, smoothies, milk, protein drinks, fruit, nut or seed butter, cheese, beans, or simple prepared protein sources. You are not trying to create an elaborate or Instagram-worthy meal—you are trying to prevent “nothing sounds good” from repeatedly becoming “I barely ate anything again today.”

Make Sure Food Apathy Is Actually the Problem

Not wanting to eat does not always mean food has lost its reward value. Sometimes the real problem is that eating has become physically unpleasant, and avoiding food is your body's attempt to avoid symptoms rather than a true loss of interest.

Persistent nausea can make you dread meals, while constipation can leave you feeling full and uncomfortable for much of the day. Reflux, abdominal discomfort, vomiting, prolonged fullness, altered taste or smell, and strong food aversions can all make eating less appealing even when the underlying reward value of food is still present.

Other factors deserve consideration too. Depression, anxiety, acute illness, poor sleep, nutritional deficiencies, and other medications can affect appetite, motivation, and energy, which means not every change that occurs while taking a GLP-1 was necessarily caused by the GLP-1.

When you say “nothing sounds good,” try to unpack what you actually mean. Does nothing sound good because you genuinely feel indifferent toward food, or because you expect eating to make you nauseated, bloated, uncomfortable, or refluxy?

Those two experiences may sound similar in casual conversation, but they point toward very different problems. Understanding which one you are experiencing gives you and your healthcare provider a much better starting point for deciding what to address.

When Should You Talk to Your Prescriber?

You do not need to contact your prescriber simply because food feels less exciting than it did before treatment. Reduced interest in eating can be part of the therapeutic effect, particularly when you are still able to eat, drink, function, and meet your nutritional needs.

You should pay closer attention when that reduced interest begins interfering with your ability to meet those needs. Repeatedly being unable to eat enough, struggling to maintain fluids, developing persistent weakness or dizziness, continuing to lose weight beyond your intended goal, or dealing with ongoing gastrointestinal symptoms are all reasons to discuss what is happening.

A major change in motivation outside food also deserves attention. There is a meaningful clinical difference between “I don't really care about eating anymore” and “I don't really care about anything anymore,” even though both may initially be described as feeling less interested in things.

The first may reflect a particularly strong effect on appetite and food reward. The second deserves a broader medical and mental-health assessment because loss of pleasure or motivation can have many causes and should not automatically be attributed to a GLP-1.

Neither situation tells you by itself exactly what caused the change. It also does not mean you should independently change, skip, lower, or stop your medication without discussing the pattern with the clinician managing your treatment.

Broader Changes in Mood or Pleasure Should Not Be Explained Away

If your loss of interest extends into the rest of your life, do not assume it is simply what happens when GLP-1 medications quiet the reward system. Loss of interest or pleasure can occur with depression and other medical or psychiatric conditions whether or not you take a GLP-1 medication.

Pay attention if you develop persistent sadness, hopelessness, major anxiety, substantial changes in sleep, increasing social withdrawal, difficulty functioning, or a broader inability to enjoy experiences that previously mattered to you. Those changes deserve appropriate clinical assessment rather than being treated as proof that the medication is simply “working really well.”

Thoughts of suicide or self-harm require urgent support and should never be dismissed as an expected medication effect. If changes in mood, motivation, or pleasure become severe or concerning, seek appropriate medical or mental-health care promptly.

From a Nurse: What I’d Pay Attention To

If you are trying to decide whether your quieter appetite is simply a welcome GLP-1 effect or whether it has become tooquiet, look less at how excited you feel about food and more at what is happening to your ability to care for yourself.

• Pay attention to what you actually eat, not just how hungry you feel. You can feel completely comfortable while consuming much less energy and nutrition than your body needs.
• Notice whether eating feels uninteresting or physically unpleasant. Nausea, constipation, reflux, abdominal discomfort, prolonged fullness, or food aversions may require a different approach than true indifference toward food.
• Look for repeated skipped meals. Missing lunch occasionally because you were busy is different from repeatedly reaching the end of the day and realizing you barely ate because food never felt worth the effort.
• Watch your hydration too. When meals become much smaller and less frequent, your usual opportunities to drink often decrease with them.
• Do not judge nutrition by protein alone. Protein matters during weight loss, but adequate overall energy, nutrients, fats, carbohydrates, fiber, and fluid still matter too.
• Pay attention to how your body is functioning. Increasing fatigue, weakness, dizziness, feeling cold, poor concentration, or declining exercise tolerance can be clues that your intake deserves a closer look, although those symptoms can also have other causes.
• Separate food from the rest of your reward system. Ask yourself whether you still enjoy your relationships, hobbies, work, movement, music, sex, travel, or whatever normally makes life feel rewarding to you.
• Tell your prescriber about broader motivational changes. “Nothing sounds good for dinner” and “nothing in my life feels enjoyable anymore” should not be treated as the same symptom.
• Do not change your medication dose on your own. If appetite suppression has become difficult to manage, your prescriber needs the full pattern so you can decide together whether anything about your treatment plan needs to change.

You do not need to force yourself to become excited about food again. What matters is that the medication reduces the pull of food without reducing your ability to adequately nourish, hydrate, and care for yourself.

When “Not Hungry” Becomes “I Don’t Care About Food”

Less hunger is an expected and often helpful GLP-1 effect. Food becoming so irrelevant that you repeatedly struggle to eat enough is different, because at that point appetite suppression is beginning to interfere with nutrition rather than simply making eating easier to regulate.

If you are less hungry, satisfied with smaller portions, experiencing less food noise, and still able to eat enough to support your health, that fits comfortably within the expected effects of GLP-1 treatment. You do not need to miss cravings or feel enthusiastic about every meal for treatment to be working appropriately.

If meals repeatedly disappear because choosing, obtaining, or eating food feels like too much effort, your appetite may have become quiet enough that you can no longer rely on hunger alone to guide your intake. Structure may need to replace appetite for a while through regular eating opportunities, easy foods, adequate fluid, and deliberate attention to your overall nutrition.

The other boundary is what happens outside food. Food-specific disinterest is not automatically anhedonia, and current population-level evidence does not show that GLP-1 medications broadly cause psychiatric problems, but a substantial loss of motivation or pleasure across other parts of your life deserves clinical assessment rather than being written off as another version of appetite suppression.

The goal of GLP-1 treatment is not to make you hungry all the time again. It is to reach a place where food can become quieter without becoming so unimportant that nourishing yourself becomes difficult.

Medical Disclaimer

GLP-1 and GIP/GLP-1 medications are prescription treatments with product-specific indications, dosing schedules, contraindications, interactions, warnings, and adverse effects. This article provides general educational information and is not intended to diagnose food aversion, malnutrition, depression, anhedonia, or any other medical or psychiatric condition.

Do not reduce, increase, stop, restart, delay, or otherwise change semaglutide, tirzepatide, or another GLP-1-based medication because of appetite, motivation, or mood changes without discussing the change with the clinician managing your treatment. Persistent inability to eat or drink adequately, repeated vomiting, dehydration, progressive weakness, significant unintentional weight loss beyond your treatment goal, or other signs of inadequate nutrition require appropriate medical assessment.

Loss of interest or pleasure extending beyond food should also be discussed with a healthcare professional, particularly when accompanied by persistent mood changes, impaired functioning, or other psychiatric symptoms. Seek urgent help for thoughts of self-harm or suicide or any immediate mental-health crisis.

Sources

1. Martin CK, Carmichael OT, Carnell S, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine. 2025. PMID: 40555748.
https://pubmed.ncbi.nlm.nih.gov/40555748/
https://doi.org/10.1038/s41591-025-03774-9

2. Quan AT, Nguyen HL, Nguyen TMT. Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2026;20(7):103466. PMID: 42508090.
https://pubmed.ncbi.nlm.nih.gov/42508090/
https://doi.org/10.1016/j.dsx.2026.103466

3. The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior.Physiology & Behavior. 2026;115486. PMID: 42641845.
https://pubmed.ncbi.nlm.nih.gov/42641845/
https://doi.org/10.1016/j.physbeh.2026.115486

4. Nadolsky S, Kessel S, Krumm ZA, Tinsley GM. Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series. Obesity Pillars. 2026;19:100302. PMID: 42518361.
https://pubmed.ncbi.nlm.nih.gov/42518361/
https://pmc.ncbi.nlm.nih.gov/articles/PMC13382402/
https://doi.org/10.1016/j.obpill.2026.100302

5. Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists. 2026. PMID: 42420795.
https://pubmed.ncbi.nlm.nih.gov/42420795/

6. Nucleus accumbens GLP-1 signaling and its role in reward and metabolic regulation: a systematic review. Frontiers in Neuroanatomy. 2026. PMID: 42534938.
https://pubmed.ncbi.nlm.nih.gov/42534938/
https://pmc.ncbi.nlm.nih.gov/articles/PMC13422549/

7. Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review. 2026.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12889473/

8. Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review. Physiology & Behavior. 2024;114622.
https://doi.org/10.1016/j.physbeh.2024.114622

9. GLP-1 influences food and drug reward. Physiology & Behavior. 2016.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4822543/

10. Eli Lilly and Company. Zepbound (tirzepatide) U.S. Prescribing Information.
https://pi.lilly.com/us/zepbound-uspi.pdf

11. Novo Nordisk. Wegovy (semaglutide) U.S. Prescribing Information.
https://www.novo-pi.com/wegovy.pdf